{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:25:47Z","timestamp":1783416347857,"version":"3.54.6"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"21","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,22]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Integrase strand transfer inhibitor (INSTI)-based regimens are recommended as first-line antiretroviral therapy for HIV-1 infection due to their potent viral suppression and high resistance barrier. However, their long-term effects are not yet fully established, primarily because persistent concerns remain regarding their adverse impacts on metabolic and renal safety in real-world use, coupled with a lack of robust comparative data on their efficacy in treatment-na\u00efve patients with primary drug resistance (PDR), which is a growing clinical challenge. This single-center, retrospective cohort study was conducted at Hangzhou Xixi Hospital, China. We enrolled treatment-na\u00efve people living with human immunodeficiency virus (HIV) initiating antiretroviral therapy between September 2023 and September 2024. According to their initial regimens, the cohort was divided into an INSTI-based group and a non-INSTI-based group. Virological, immunological, metabolic, and renal parameters were assessed at baseline and after 12 months of treatment. Inter-group comparisons of changes from baseline to month 12 were performed using multiple linear regression models, with results expressed as adjusted mean differences. Other statistical analyses included\n                      <jats:italic toggle=\"yes\">t<\/jats:italic>\n                      tests, Mann\u2013Whitney\n                      <jats:italic toggle=\"yes\">U<\/jats:italic>\n                      tests, and chi-square tests, as appropriate. HIV drug resistance mutations were analyzed using sequencing and the Stanford University HIV Drug Resistance Database. This study included 304 treatment-na\u00efve patients, with a median age of 29 years, and male patients accounted for 94.1%. Both regimens achieved high and comparable virological suppression rates and similar CD4 cell recovery. However, the INSTI-based regimen was associated with significantly greater increases in total cholesterol (adjusted mean difference: 0.34 mmol\/L,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.001), triglycerides (0.49 mmol\/L,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.002), and serum creatinine (9.8 \u03bcmol\/L,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.001), and a greater decline in estimated glomerular filtration rate (\u221215\u2009mL\/min,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.001). Among 14 patients with PDR, all 13 receiving an INSTI-based regimen achieved virological suppression, whereas the single patient on a non-INSTI-based regimen experienced virological failure. While demonstrating comparable overall effectiveness at 12 months, INSTI-based regimens were associated with less favorable lipid and renal safety profiles compared with non-INSTI-based regimens. Critically, INSTI-based regimens showed superior efficacy in patients with PDR. In conclusion, our findings support the use of INSTI-based regimens, particularly for patients with PDR, but mandate enhanced monitoring and management of lipid profiles and renal function. Prospective studies with larger sample sizes are warranted to confirm the long-term clinical implications of these findings.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000048891","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T17:01:55Z","timestamp":1779469315000},"page":"e48891","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Comparative effectiveness and safety of integrase strand transfer inhibitor (INSTI)-based versus non-INSTI-based antiretroviral regimens in treatment-na\u00efve people with HIV: A real-world retrospective cohort study"],"prefix":"10.1097","volume":"105","author":[{"given":"Xiafen","family":"Ye","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, Hangzhou Xixi Hospital, Hangzhou Sixth People\u2019s Hospital, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Han","sequence":"additional","affiliation":[{"name":"Department II of Infectious Diseases, Hangzhou Xixi Hospital, Hangzhou Sixth People\u2019s Hospital, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazhen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Hangzhou Xixi Hospital, Hangzhou Sixth People\u2019s Hospital, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunli","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The 903rd Hospital of PLA, Hangzhou, Zhejiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongbao","family":"Zuo","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Hangzhou Xixi Hospital, Hangzhou Sixth People\u2019s Hospital, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Hangzhou Xixi Hospital, Hangzhou Sixth People\u2019s Hospital, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanlan","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Hangzhou Xixi Hospital, Hangzhou Sixth People\u2019s Hospital, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Hangzhou Xixi Hospital, Hangzhou Sixth People\u2019s Hospital, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaochan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Hangzhou Xixi Hospital, Hangzhou Sixth People\u2019s Hospital, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaizhong","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Hangzhou Xixi Hospital, Hangzhou Sixth People\u2019s Hospital, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0932-7688","authenticated-orcid":false,"given":"Xiaoqiang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Hangzhou Xixi Hospital, Hangzhou Sixth People\u2019s Hospital, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260707","first-page":"927","article-title":"National HIV\/STD epidemic situation in June 2025.","volume":"31","year":"2025","journal-title":"Chin J AIDS STD"},{"key":"R2-20260707","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.tips.2021.10.004","article-title":"Update and latest advances in antiretroviral therapy.","volume":"43","author":"Men\u00e9ndez-Arias","year":"2022","journal-title":"Trends Pharmacol Sci"},{"key":"R3-20260707","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1016\/S2352-3018(17)30066-8","article-title":"Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies.","volume":"4","year":"2017","journal-title":"Lancet HIV"},{"key":"R4-20260707","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1097\/CM9.0000000000003383","article-title":"Chinese guidelines for the diagnosis and treatment of human immunodeficiency virus infection\/acquired immunodeficiency syndrome (2024 edition).","volume":"137","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"R5-20260707","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0140-6736(07)60597-2","article-title":"Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.","volume":"369","author":"Grinsztejn","year":"2007","journal-title":"Lancet"},{"key":"R6-20260707","first-page":"867","article-title":"Chinese guidelines for diagnosis and treatment of HIV\/AIDS (2018).","volume":"57","year":"2018","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"R7-20260707","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society-USA Panel.","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"key":"R8-20260707","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ijantimicag.2019.08.008","article-title":"Meta-analysis and systematic review of the efficacy and resistance for human immunodeficiency virus type 1 integrase strand transfer inhibitors.","volume":"54","author":"Yang","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"R9-20260707","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1016\/S2352-3018(23)00328-4","article-title":"Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts.","volume":"11","author":"Byonanebye","year":"2024","journal-title":"Lancet HIV"},{"key":"R10-20260707","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1177\/09564624241287886","article-title":"Incidence of non-alcoholic fatty liver disease in antiretroviral therapy-na\u00efve people with human immunodeficiency virus who start DTG\/ABC\/3TC compared to BIC\/FTC\/TAF at 48-week follow-up.","volume":"36","author":"D\u00edaz","year":"2025","journal-title":"Int J STD AIDS"},{"key":"R11-20260707","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/cid\/ciae645","article-title":"Metabolic complications after initiating BIC\/FTC\/TAF versus DTG + 3TC in antiretroviral-therapy-naive adults with HIV: a multicenter prospective cohort study.","volume":"81","author":"de Morales","year":"2025","journal-title":"Clin Infect Dis"},{"key":"R12-20260707","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1089\/aid.2011.0275","article-title":"Lopinavir\/ritonavir combined with raltegravir or tenofovir\/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study.","volume":"29","author":"Reynes","year":"2013","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R13-20260707","doi-asserted-by":"crossref","first-page":"e25611","DOI":"10.1002\/jia2.25611","article-title":"HIV-1 transmitted drug resistance surveillance: shifting trends in study design and prevalence estimates.","volume":"23","author":"Rhee","year":"2020","journal-title":"J Int AIDS Soc"},{"key":"R14-20260707","doi-asserted-by":"crossref","first-page":"664","DOI":"10.46234\/ccdcw2023.129","article-title":"Changes in HIV-1 subtypes\/sub-subtypes, and transmitted drug resistance among ART-na\u00efve HIV-infected individuals - China, 2004\u20132022.","volume":"5","author":"Liu","year":"2023","journal-title":"China CDC Wkly"},{"key":"R15-20260707","doi-asserted-by":"crossref","first-page":"e50894","DOI":"10.2196\/50894","article-title":"Pretreatment HIV drug resistance and the molecular transmission network among HIV-positive individuals in China in 2022: multicenter observational study.","volume":"9","author":"Chen","year":"2023","journal-title":"JMIR Public Health Surveill"},{"key":"R16-20260707","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.3390\/v17111516","article-title":"Network dynamics and evolutionary drivers of HIV drug resistance in eastern China, from 2022 to 2024.","volume":"17","author":"Cao","year":"2025","journal-title":"Viruses"},{"key":"R17-20260707","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1093\/jac\/dky005","article-title":"Primary resistance to integrase strand transfer inhibitors in patients infected with diverse HIV-1 subtypes in sub-Saharan Africa.","volume":"73","author":"Inzaule","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"R18-20260707","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/cid\/ciac972","article-title":"Transmitted drug resistance to integrase-based first-line human immunodeficiency virus antiretroviral regimens in Mediterranean Europe.","volume":"76","author":"de Salazar","year":"2023","journal-title":"Clin Infect Dis"},{"key":"R19-20260707","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3390\/v16020239","article-title":"HIV-1 drug resistance detected by next-generation sequencing among ART-na\u00efve individuals: a systematic review and meta-analysis.","volume":"16","author":"Ouyang","year":"2024","journal-title":"Viruses"},{"key":"R20-20260707","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1038\/s41598-024-53282-y","article-title":"Dolutegravir based therapy showed CD4(+) T cell count recovery and viral load suppression among ART na\u00efve people living with HIV AIDS: a pilot evaluation.","volume":"14","author":"Gebremedhin","year":"2024","journal-title":"Sci Rep"},{"key":"R21-20260707","doi-asserted-by":"crossref","first-page":"103055","DOI":"10.1016\/j.jiph.2025.103055","article-title":"Enhanced immune recovery with B\/F\/TAF compared with DTG\/3TC in HIV patients: a prospective observational study.","volume":"19","author":"Fan","year":"2025","journal-title":"J Infect Public Health"},{"key":"R22-20260707","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/cid\/ciaf159","article-title":"Transmitted HIV-1 drug resistance among newly diagnosed individuals in 31 provincial-level administrative divisions in China in 2023: a cross-sectional survey.","volume":"81","author":"Hao","year":"2025","journal-title":"Clin Infect Dis"},{"key":"R23-20260707","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jcv.2018.06.012","article-title":"Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): durability and virological response in a large Italian HIV drug resistance network (ARCA).","volume":"105","author":"Rusconi","year":"2018","journal-title":"J Clin Virol"},{"key":"R24-20260707","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12981-024-00681-w","article-title":"Effectiveness of dolutegravir-based regimens compared to raltegravir-, elvitegravir-, bictegravir, and darunavir-based regimens among older adults with HIV in the Veterans Aging Cohort Study (VACS).","volume":"21","author":"Yan","year":"2024","journal-title":"AIDS Res Ther"},{"key":"R25-20260707","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1124\/mol.111.073189","article-title":"Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S\/GSK1349572).","volume":"80","author":"Hare","year":"2011","journal-title":"Mol Pharmacol"},{"key":"R26-20260707","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12879-023-08910-9","article-title":"Dyslipidemia among HIV-infected patients in Ethiopia: a systematic review and meta-analysis.","volume":"24","author":"Mohammed","year":"2024","journal-title":"BMC Infect Dis"},{"key":"R27-20260707","first-page":"203","article-title":"Spectrum and correlates of dyslipidemia in people living with HIV on dolutegravir-based regimen attending Kabutare Hospital, Southern Rwanda: a cross-sectional study.","volume":"17","author":"Nsengumuremyi","year":"2025","journal-title":"HIV AIDS (Auckl)"},{"key":"R28-20260707","doi-asserted-by":"crossref","first-page":"4620951","DOI":"10.1155\/2024\/4620951","article-title":"Weight and lipid levels in people living with HIV and initiating a dolutegravir-based regimen in a resource limited setting: a prospective study.","volume":"2024","author":"Chakanetsa","year":"2024","journal-title":"AIDS Res Treat"},{"key":"R29-20260707","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41572-020-0181-1","article-title":"HIV and antiretroviral therapy-related fat alterations.","volume":"6","author":"Koethe","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"R30-20260707","doi-asserted-by":"crossref","first-page":"ofab537","DOI":"10.1093\/ofid\/ofab537","article-title":"Assessment of obesity and cardiometabolic status by integrase inhibitor use in REPRIEVE: a propensity-weighted analysis of a multinational primary cardiovascular prevention cohort of people with human immunodeficiency virus.","volume":"8","author":"Kileel","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"R31-20260707","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2352-3018(24)00183-8","article-title":"Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration.","volume":"11","author":"Pantazis","year":"2024","journal-title":"Lancet HIV"},{"key":"R32-20260707","first-page":"1367","article-title":"Weight gain in HIV adults receiving antiretroviral treatment: current knowledge and future perspectives.","volume":"14","author":"Markakis","year":"2024","journal-title":"Life (Basel)"},{"key":"R33-20260707","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s11904-024-00708-x","article-title":"Metabolic complications associated with use of integrase strand transfer inhibitors (InSTI) for the treatment of HIV-1 infection: focus on weight changes, lipids, glucose and bone metabolism.","volume":"21","author":"Savinelli","year":"2024","journal-title":"Curr HIV\/AIDS Rep"},{"key":"R34-20260707","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","article-title":"Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.","volume":"381","author":"Raffi","year":"2013","journal-title":"Lancet"},{"key":"R35-20260707","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med"},{"key":"R36-20260707","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.2147\/IDR.S347054","article-title":"Comparison of renal function biomarkers of serum creatinine and cystatin C in HIV-infected people on dolutegravir-containing therapy.","volume":"15","author":"Lu","year":"2022","journal-title":"Infect Drug Resist"},{"key":"R37-20260707","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/cid\/ciaf049","article-title":"Noninvasive markers of hepatic steatosis and fibrosis following integrase strand-transfer inhibitor initiation in women with HIV.","volume":"81","author":"Yu","year":"2025","journal-title":"Clin Infect Dis"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048891","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:01:42Z","timestamp":1783414902000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":37,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048891","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"2026-01-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}